Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate - Benzinga - Benzinga

• Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and manufacture its COVID-19 vaccine candidate.
• Emergent will produce drug substances for Providence's vaccine candidate, PTX-COVID19-B, and provide services for finished products at its Winnipeg facility in Canada.
• Emergent expects to manufacture tens of millions of doses of Providence's shot in 2022 and batches of formulated bulk drug substances for the vaccine.
• The agreement covers the cost for manufacturing services, studies to support global supply chain activities, and facility and equipment investments.
• Price Action: EBS shares traded lower by 1.10% at $56.75 on the last check Tuesday.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Adblock test (Why?)

Read Again https://www.benzinga.com/general/biotech/21/09/22930114/emergent-secures-contract-to-manufacture-providence-therapeutics-covid-19-vaccine-candidate

Bagikan Berita Ini